AbbVie Inc. took a big dive into the increasingly popular antibody-drug conjugate space on 30 November with a $10.1bn buyout offer for ImmunoGen, Inc. and its ovarian cancer ADC Elahere. It also took an attractive takeover option off the board in a field where the Chicago-area big pharma has long wanted to build a significant presence.
Key Takeaways
-
AbbVie will pay $10.1bn to acquire ImmunoGen and Elahere, the first antibody-drug conjugate approved to treat ovarian cancer.
The deal comes six-years after AbbVie made an ill-fated $5.8bn wager on Stemcentrx and its DLL3-targeting ADC candidate for lung...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?